Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
53 participants
INTERVENTIONAL
2025-03-03
2025-11-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Assess the pharmacokinetics of metatine and nicotine electronic (e)-cigarettes.
II. Assess the abuse liability and appeal of commercial e-cigarettes containing metatine versus nicotine.
III. Determine the impact of metatine on e-cigarette puffing behavior (topography).
OUTLINE: Participants attend 3 sessions where they will be randomized to 1 of 3 types of e-cigarette. Participants will use the e-cigarette ad-libitum for 30 minutes and answer survey questions about their perceptions of the e-cigarette. Participants must also undergo 4 blood draws during the vaping session.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participant's personal nicotine e-cigarette
The study participant's own preferred e-cigarette will be used for this condition.
Biospecimen Collection
Undergo blood sample collection
Survey Administration
Complete Surveys
Vaping Topography
Use e-cigarette connected to a topography device
Participant's Own Preferred E-cigarette
Participant vapes their own preferred e-cigarette for 30 minutes
Nicotine e-cigarette
A fruit flavored commercially available nicotine e-cigarette will be used for this condition.
Biospecimen Collection
Undergo blood sample collection
Survey Administration
Complete Surveys
Vaping Topography
Use e-cigarette connected to a topography device
Nicotine E-cigarette
Participant vapes a commercially available nicotine e-cigarette for 30 minutes
6-methyl nicotine (metatine) e-cigarette
A fruit flavored commercially available metatine e-cigarette will be used for this condition.
Biospecimen Collection
Undergo blood sample collection
Survey Administration
Complete Surveys
Vaping Topography
Use e-cigarette connected to a topography device
6-methyl-nicotine (metatine) e-cigarette
Participant vapes a commercially available metatine e-cigarette for 30 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biospecimen Collection
Undergo blood sample collection
Survey Administration
Complete Surveys
Vaping Topography
Use e-cigarette connected to a topography device
Participant's Own Preferred E-cigarette
Participant vapes their own preferred e-cigarette for 30 minutes
Nicotine E-cigarette
Participant vapes a commercially available nicotine e-cigarette for 30 minutes
6-methyl-nicotine (metatine) e-cigarette
Participant vapes a commercially available metatine e-cigarette for 30 minutes
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current nicotine EC user (defined as ≥ weekly use over the past 3 months)
* Willing to provide informed consent and abstain from using any e-cigarette at least 12 hours prior to the three lab sessions
* Read and speak English
Exclusion Criteria
* Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
* History of cardiac event or distress within the past 3 months
* Have suffered from any serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days
* Are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test)
* Have hemophilia or another type of bleeding disorder
* Are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability
21 Years
34 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ohio State University Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alayna Tackett
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alayna P Tackett, PhD
Role: PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The Jamesline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OSU-24276
Identifier Type: -
Identifier Source: org_study_id
NCI-2024-10267
Identifier Type: REGISTRY
Identifier Source: secondary_id